Vistra Q3 Beat Lifts Guidance, But Timing Questions Linger

What happened

Vistra's Q3 2026 results handily beat expectations, with EPS surging 84.6% year-over-year on stronger power pricing and retail margins, while revenue climbed 27.7%. Management responded by raising full-year 2026 EBITDA guidance, reinforcing the near-term earnings power of the integrated generation and retail model. This comes after the company's August guidance reaffirmation of $6.72-$7.52 billion, suggesting the high end is now more likely, but the update does not address the central timing risks around Cogentrix closing, Meta delivery commencement, or ERCOT large-load verification. The DeepValue report had rated Vistra a WAIT at $147.10, citing a lack of margin of safety due to valuation and delayed ERCOT monetization; the strong quarter improves the earnings bridge but does not change the fact that key catalysts remain in 2027-2028. If the stock has rallied on this news, it likely reduces the attractiveness relative to the $135 entry threshold, though the fundamental business remains solid.

Implication

Investors should view the Q3 beat as confirmation that Vistra's diversified model can deliver strong earnings even without AI-driven ERCOT upside, which supports the downside protection at current levels. However, the raised 2026 guidance is likely already discounted in the stock price after the earnings pop, and the valuation still sits above the WAIT threshold of $135. The key catalysts for re-rating remain Cogentrix closing (expected late 2026), Meta operating delivery start (late 2026), and evidence of ERCOT verification progress, none of which were updated in this earnings call. Until those milestones are met, the stock may remain range-bound as the market waits for proof of the 2027-2028 earnings bridge. A better entry would be on a pullback toward $135, where the contracted PJM cash flows and retail earnings provide a clearer margin of safety.

Thesis delta

The original thesis was WAIT due to lack of margin of safety at $147, with value drivers mostly in 2027+. The Q3 beat and raised guidance demonstrate that current operations are performing above plan, which modestly strengthens the base-case earnings and reduces downside risk. However, the core timing uncertainties (Cogentrix, Meta, ERCOT) are unchanged, and if the stock has rallied above $150, the margin of safety has narrowed further. Therefore, the WAIT rating remains appropriate, with no change to the attractive entry of $135.